Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
132 hedge funds and large institutions have $1.53B invested in Intra-Cellular Therapies Inc. in 2015 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 38 reducing their positions, and 22 closing their positions.
38% more capital invested
Capital invested by funds: $1.11B → $1.53B (+$419M)
34% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 38
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
3% more funds holding
Funds holding: 128 → 132 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
65% less call options, than puts
Call options by funds: $5.66M | Put options by funds: $16.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$43.2M |
| 2 |
Millennium Management
New York
|
+$22.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.1M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$15.6M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.8M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$17.4M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$14.9M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.6M |
| 5 |
Morgan Stanley
New York
|
-$10.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
SG Americas Securities
New York
| – | -$119K | -2,977 | Closed |
|
|
PG
152
PEAK6 Group
Chicago,
Illinois
| – | -$96K | -2,400 | Closed |
|
|
PAM
153
Panagora Asset Management
Boston,
Massachusetts
| – | -$67K | -1,684 | Closed |
|
|
QT
154
Quantbot Technologies
New York
| – | -$24K | -616 | Closed |
|
ITCI Hedge Fund Activity: Q4 2015 in Review
132 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2015, worth a combined $1.53B — up 38% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ITCI positions and 22 closed out — a net gain of 4 holders — while 51 added to existing stakes and 38 trimmed.
The largest buyer was Jennison Associates, adding an estimated $43.2M. The largest seller was State Street, cutting an estimated $18.8M.
- 132 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2015, up from 128 in Q3 2015.
- Funds reported $1.53B of Intra-Cellular Therapies Inc. stock for Q4 2015, up 38% quarter-over-quarter.
- 26 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2015 and 22 closed out, a net change of +4 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2015 was Jennison Associates, an estimated $43.2M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2015 was State Street, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2015.